K. Thierauch

W. Luttmann, K. Thierauch, S. Fais, 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours.

E. Dahl, A. Rosenthal, D. Mennerich, 2004, European journal of cancer.

Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1β and TNFα

W. Luttmann, K. Thierauch, M. Davies, 1993 .

Abstract B4: Regorafenib: a new oral multikinase inhibitor of angiogenic, stromal and oncogenic (receptor tyrosine) kinases with potent preclinical antitumor activity

J. Hornberg, D. Zopf, K. Thierauch, 2009 .

Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites

D. Zopf, K. Thierauch, S. Wilhelm, 2010 .

Ureotelism as the prevailing mode of nitrogen excretion in larvae of the marsupial frog Gastrotheca riobambae (Fowler) (Anura, Hylidae).

H. Steinbeisser, K. Thierauch, I. Alcocer, 1992, Comparative biochemistry and physiology. Comparative physiology.

Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.

K. Thierauch, F. Kruse, C. Cursiefen, 2008, Investigative ophthalmology & visual science.

[Tritium-labeled reactive analogs of [1,6-alpha-aminosuberic acid, 8-arginine] vasopressin (deamino-dicarba-[8-arginine] vasopressin. synthesis and properties].

F. Fahrenholz, K. Thierauch, J. Morgat, 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

Differential gene expression by endothelial cells in distinct angiogenic states.

C. Pilarsky, A. Rosenthal, A. Schmitt, 2000, European journal of biochemistry.

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

A. Rosenthal, Robert Schmieder, D. Zopf, 2014, International journal of cancer.

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J. Mestan, F. Totzke, G. Martiny-Baron, 2000, Cancer research.

BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I

A. Ehrmann, K. Thierauch, K. Ziegelbauer, 2013, Cancer medicine.

LDH-A influences hypoxia-inducible factor 1α (HIF1 α) and is critical for growth of HT29 colon carcinoma cells in vivo

K. Thierauch, H. Hess-Stumpp, S. Langhammer, 2011, Targeted Oncology.

Human SPRY2 inhibits FGF2 signalling by a secreted factor

K. Thierauch, J. Glienke, A. Sturz, 2000, Mechanisms of Development.

Synthesis of p-amino-L-phenylalanine derivatives with protected p-amino group for preparation of p-azido-L-phenylalanine peptides.

F. Fahrenholz, K. Thierauch, 2009, International journal of peptide and protein research.

Synthesis and biological activities of arginine-vasopressin analogues with reactive groups.

F. Fahrenholz, K. Thierauch, P. Crause, 1980, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

PTK 787/ZK 222584, a Tyrosine Kinase Inhibitor of all Known VEGF Receptors, Represses Tumor Growth with High Efficacy

K. Thierauch, H. Hess-Stumpp, M. Haberey, 2005, Chembiochem : a European journal of chemical biology.

Vascular Endothelial Growth Factor (VEGF) Receptor II-derived Peptides Inhibit VEGF*

J. Schneider-Mergener, L. Germeroth, M. Schirner, 1999, The Journal of Biological Chemistry.

Novel antibodies directed against the extracellular domain of the human VEGF-receptor type II.

G. Martiny-Baron, A. Menrad, G. Siemeister, 1997, Hybridoma.

Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2

H. Augustin, J. Schneider-Mergener, M. Bachmann, 2003, Thrombosis and Haemostasis.

Prostaglandins and their receptors

K. Thierauch, H. Dinter, G. Stock, 1996 .

Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.

D. Jackson, B. Wiedenmann, M. Schirner, 2005, International journal of oncology.

Kinase Inhibitors: Cancer Drugs Derived from Mechanistic Considerations

K. Thierauch, A. Chlistalla, 2007 .

Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha.

W. Luttmann, K. Thierauch, M. Davies, 1993, Kidney international.

Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.

J. Mestan, C. Schnell, J. Wood, 2002, Journal of medicinal chemistry.

CRIM1 is involved in endothelial cell capillary formation in vitro and is expressed in blood vessels in vivo

A. Menrad, K. Thierauch, J. Glienke, 2002, Mechanisms of Development.

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

I. Fichtner, D. Zopf, K. Thierauch, 2016, Cancer medicine.

Abstract 4509: BAY 87-2243 targets hypoxia-induced activation and stabilization of HIF-1α: A novel approach to overcome resistance mechanisms in cancer therapy

K. Thierauch, S. Wilhelm, K. Ziegelbauer, 2011 .

Modulation of platelet activation by prostaglandin E2 mimics.

K. Thierauch, G. Prior, 1991, Advances in prostaglandin, thromboxane, and leukotriene research.